Pichia pastoris is emerging as a versatile, efficient alternative for protein production, bridging microbial and mammalian expression systems.

Protalix ( ($PLX) ) has issued an update. On November 3, 2025, Protalix BioTherapeutics and Chiesi Global Rare Diseases announced their request ...

A case of membranoproliferative glomerulonephritis with immune depositions in the kidney was reported during clinical trials. Monitor serum creatinine and urinary protein-to-creatinine ratio. If ...

Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), ...

production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system," issued a press release on October 17, 2025, ...

The collaboration between the University and CyanoCapture will focus on developing innovative methods for producing targeted delivery systems using engineered carboxysomes, combining advanced ...

The University of Liverpool rand CyanoCapture Ltd are joining forces to develop the next generation of carboxysome-based ...

Pomerantz LLP is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. ("Protalix" or the "Company") . Such investors are advised to contact Danielle Peyton at newaction@pomlaw ...

“Dyadic is advancing its transition to ... These high-quality proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic’s C1 and Dapibus™ ...

This important study presents a thoughtful design and characterization of chimeric influenza hemagglutinin (HA) head domains combining elements of distinct receptor-binding sites. The results provide ...